



## Jeffrey S. Glenn, M.D., Ph.D.

Joseph D. Grant Professor and Professor of Microbiology and Immunology  
Medicine - Gastroenterology & Hepatology

### CLINICAL OFFICE (PRIMARY)

- **Stanford Gastroenterology**

269 Campus Dr Rm 3115

CCSR Bldg MC 5171

Stanford, CA 94305

**Tel** (650) 725-3373      **Fax** (650) 723-3032

### Bio

---

#### BIO

Dr. Glenn's primary interest is in molecular virology, with a strong emphasis on translating this knowledge into novel antiviral therapies. Current projects aim to better understand the role of prenylation in the life cycles of hepatitis delta virus (HDV) and other viruses--both as a mechanism of intracellular trafficking and trigger of virus assembly, and as a target for a promising antiviral treatment. The function and cell biology of hepatitis and respiratory virus proteins are also being studied, with a focus on identifying key determinants of pathogenesis and designing novel antiviral strategies for hepatitis, influenza, and enteroviruses. Of particular interest are targets in host cells upon which viruses depend, and critical RNA secondary structures in viruses. Other interests include exploitation of hepatic stem cells, development of small animal models, NASH, liver cancer, and engineered human liver tissues.

#### CLINICAL FOCUS

- Gastroenterology

#### ACADEMIC APPOINTMENTS

- Professor, Medicine - Gastroenterology & Hepatology
- Professor, Microbiology and Immunology
- Member, Bio-X
- Member, Maternal & Child Health Research Institute (MCHRI)
- Faculty Fellow, Sarafan ChEM-H
- Member, Stanford Cancer Institute
- Member, Wu Tsai Neurosciences Institute

#### ADMINISTRATIVE APPOINTMENTS

- Director, ViRx@Stanford--Stanford Biosecurity and Pandemic Preparedness Initiative, (2021- present)
- Director, Center for Hepatitis and Liver Tissue Engineering, (2006- present)

## HONORS AND AWARDS

- Translational Research Award, American Liver Foundation/Amgen/AASLD (1998-2002)
- Regents Scholarship, U.C.S.F. (1984-1993)
- Elected member, American Society for Clinical Investigation (2008)
- Clinical Scientist Award in Translational Research, Burroughs Wellcome Fund (2005-2010)
- Career Award, Burroughs Wellcome Fund (1998-2005)
- Physician Postdoctoral Fellowship Award, Howard Hughes Medical Institute (1995-1998)
- Summa cum laude, U.C. Berkeley (1984)

## PROFESSIONAL EDUCATION

- Fellowship: Stanford University Division of Gastroenterology and Hepatology (1998) CA
- Board Certification: Gastroenterology, American Board of Internal Medicine (2018)
- Residency: Stanford University Internal Medicine Residency (1995) CA
- Medical Education: University of California at San Francisco School of Medicine (1993) CA
- Ph.D., U.C.S.F. , Biochemistry and Biophysics (1992)
- M.D., U.C.S.F. , Medicine/MSTP (1993)

## LINKS

- ViRx@Stanford: <https://virx.stanford.edu>

## Research & Scholarship

---

### CURRENT RESEARCH AND SCHOLARLY INTERESTS

Dr. Glenn's primary interest is in molecular virology, with a strong emphasis on translating this knowledge into novel antiviral therapies. Current projects aim to better understand the role of prenylation in the life cycles of hepatitis delta virus (HDV) and other viruses--both as a mechanism of intracellular trafficking and trigger of virus assembly, and as a target for a promising antiviral treatment. The function and cell biology of hepatitis and respiratory virus proteins are also being studied, with a focus on identifying key determinants of pathogenesis and designing novel antiviral strategies for hepatitis, influenza, and enteroviruses. Of particular interest are targets in host cells upon which viruses depend, and critical RNA secondary structures in viruses. Other interests include exploitation of hepatic stem cells, development of small animal models, NASH, liver cancer, and engineered human liver tissues.

## Teaching

---

### GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Gastroenterology & Hepatology (Fellowship Program)
- Infectious Diseases (Fellowship Program)
- Medicine (Masters Program)
- Microbiology and Immunology (Phd Program)

## Publications

---

### PUBLICATIONS

- **Pegylated Interferon Lambda for Covid-19. Reply.** *The New England journal of medicine*  
Reis, G., Mills, E. J., Glenn, J. S.  
2023; 388 (22): 2108

- **Treatment of chronic hepatitis d with peginterferon lambda - the phase 2 LIMT-1 clinical trial.** *Hepatology (Baltimore, Md.)*  
Etzion, O., Hamid, S., Lurie, Y., Gane, E. J., Yardeni, D., Duehren, S., Bader, N., Nevo-Shor, A., Channa, S. M., Cotler, S. J., Mawani, M., Parkash, O., Dahari, et al  
2023
- **Early Treatment with Pegylated Interferon Lambda for Covid-19.** *The New England journal of medicine*  
Reis, G., Moreira Silva, E. A., Medeiros Silva, D. C., Thabane, L., Campos, V. H., Ferreira, T. S., Santos, C. V., Nogueira, A. M., Almeida, A. P., Savassi, L. C., Figueiredo-Neto, A. D., Dias, A. C., Freire Júnior, et al  
2023; 388 (6): 518-528
- **Programmable Antivirals and Just-in-Time Vaccines: Biosecurity Implications of Viral RNA Secondary Structure Targeting.** *Health security*  
Pannu, J., Glenn, J. S.  
2022
- **FUNCTIONAL CURE WITH LONAFARNIB-BASED THERAPY IN CHRONIC HEPATITIS DELTA**  
Yurdaydin, C., Yurdcu, E., Gumussoy, M., Keskin, O., Gencdal, G., Akyildiz, M., Zeybel, M., Idilman, R., Bozdayi, M., Choong, I., Glenn, J.  
WILEY.2022: S297-S298
- **Modeling the Interplay between HDV and HBV in Chronic HDV/HBV Patients** *MATHEMATICS*  
Mhlanga, A., Zakh, R., Churkin, A., Reinharz, V., Glenn, J. S., Etzion, O., Cotler, S. J., Yurdaydin, C., Barash, D., Dahari, H.  
2022; 10 (20)
- **ESTIMATING HEPATITIS DELTA PREVALENCE AMONG HIGH RISK POPULATIONS IN THE UNITED STATES: A SYSTEMATIC REVIEW**  
Wong, R. J., Brosgart, C. L., Wong, S. S., Feld, J. J., Glenn, J., Moraras, K., Hamid, S. S., Ward, J. W., Wedemeyer, H., Yurdaydin, C., Gish, R. G.  
WILEY.2022: S254-S255
- **ESTIMATING THE PREVALENCE OF CHRONIC HEPATITIS B AMONG FOREIGN-BORN PERSONS LIVING IN CANADA BY COUNTRY OF ORIGIN**  
Wong, R. J., Brosgart, C. L., Wong, S. S., Feld, J. J., Hirode, G., Glenn, J., Hamid, S. S., Moraras, K., Ward, J. W., Wedemeyer, H., Yurdaydin, C., Gish, R. G.  
WILEY.2022: S261-S262
- **Programmable antivirals to target conserved essential shapes in pandemic viral genomes** *NATURE MEDICINE*  
Glenn, J. S.  
2022
- **Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2.** *Nature medicine*  
Hagey, R. J., Elazar, M., Pham, E. A., Tian, S., Ben-Avi, L., Bernardin-Souibgui, C., Yee, M. F., Moreira, F. R., Rabinovitch, M. V., Meganck, R. M., Fram, B., Beck, A., Gibson, et al  
2022
- **Lonafarnib combination with peginterferon Lambda diminished triphasic HDV kinetic pattern seen under Lambda monotherapy: the LIFT HDV study**  
Duehren, S., Koh, C., Hercun, J., Rahman, F., Surana, P., Vittal, A., Lai, W., Etzion, O., Cotler, S., Glenn, J., Dahari, H., Heller, T.  
ELSEVIER.2022: S70-S71
- **Mathematical modeling of HDV RNA kinetics suggests high peginterferon Lambda efficacy in blocking viral production: insights from the LIMT-1 study**  
Cardozo-Ojeda, E., Duehren, S., Hamid, S., Lurie, Y., Gane, E. J., Nevo-Shor, A., Yardeni, D., Cotler, S., Choong, I., Glenn, J., Dahari, H., Etzion, O.  
ELSEVIER.2022: S859
- **Estimating the prevalence of hepatitis delta infection among foreign-born adults with chronic hepatitis B in the United States**  
Wong, R., Brosgart, C., Wong, S., Feld, J., Glenn, J., Hamid, S., Moraras, K., Ward, J., Wedemeyer, H., Yurdaydin, C., Gish, R. G.  
ELSEVIER.2022: S274
- **First-in-human experience using RBS2418, an oral ENPP1 inhibitor within an expanded access protocol in combination with pembrolizumab in a patient with metastatic adrenal cancer.**  
Csiki, I., Dong, A., Tuan, B. Y., John, E., O'Toole, L., Seppa, J., Huang, N., Hawley, R. C., Exon, C., Glenn, J. S., Klumpp, K.  
LIPPINCOTT WILLIAMS & WILKINS.2022

- **Combination of Novel Therapies for HDV.** *Viruses*  
Elazar, M., Glenn, J. S.  
2022; 14 (2)
- **Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical Trial.** *Evidence-based complementary and alternative medicine : eCAM*  
Hassanein, T., Tai, D., Liu, C., Box, T. D., Tong, M. J., Rossaro, L., Pozza, R., Glenn, J. S., Cheung, R., Hemaidan, A., He, Y., Behling, C., Hu, et al  
2022; 2022: 4494099
- **A Phase ii dose finding study of Isoniazid and ritonavir with or without interferon alpha for chronic delta hepatitis.** *Hepatology (Baltimore, Md.)*  
Yurdaydin, C., Keskin, O., Yurdcu, E., Caliskan, A., Onem, S., Karakaya, F., Kalkan, C., Karatayli, E., Karatayli, S., Choong, I., Apelian, D., Koh, C., Heller, et al  
2021
- **Hepatitis Delta Virus Testing and Research.** *Gastroenterology & hepatology*  
Glenn, J. S.  
2021; 17 (10): 482-484
- **HEPATITIS D VIRUS INFECTION IN UNITED STATES WOMEN WITH OR AT RISK FOR HIV**  
Argiron, I., Mahale, P., Kuniholm, M. H., Pfeiffer, R., Koshiol, J., Glenn, J., O'Brien, T. R.  
WILEY.2021: 422A
- **Cryo-EM and antisense targeting of the 28-kDa frameshift stimulation element from the SARS-CoV-2 RNA genome.** *Nature structural & molecular biology*  
Zhang, K., Zheludev, I. N., Hagey, R. J., Haslecker, R., Hou, Y. J., Kretsch, R., Pintilie, G. D., Rangan, R., Kladwang, W., Li, S., Wu, M. T., Pham, E. A., Bernardin-Souibgui, et al  
2021
- **Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3-amplified lung adenocarcinoma cells.** *Proceedings of the National Academy of Sciences of the United States of America*  
Shi, L., Tan, X., Liu, X., Yu, J., Bota-Rabassedas, N., Niu, Y., Luo, J., Xi, Y., Zong, C., Creighton, C. J., Glenn, J. S., Wang, J., Kurie, et al  
2021; 118 (25)
- **Publisher Correction: A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.** *Nature*  
Dinnon, K. H., Leist, S. R., Schäfer, A. n., Edwards, C. E., Martinez, D. R., Montgomery, S. A., West, A. n., Yount, B. L., Hou, Y. J., Adams, L. E., Gully, K. L., Brown, A. J., Huang, et al  
2021
- **Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy.** *Alimentary pharmacology & therapeutics*  
Hercun, J., Kim, G. E., Da, B. L., Rotman, Y., Kleiner, D. E., Chang, R., Glenn, J. S., Hoofnagle, J. H., Koh, C., Heller, T.  
2021
- **Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination.** *Proceedings of the National Academy of Sciences of the United States of America*  
Lopez Angel, C. J., Pham, E. A., Du, H. n., Vallania, F. n., Fram, B. J., Perez, K. n., Nguyen, T. n., Rosenberg-Hasson, Y. n., Ahmed, A. n., Dekker, C. L., Grant, P. M., Khatri, P. n., Maecker, et al  
2021; 118 (14)
- **Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.** *Nature communications*  
Jagannathan, P. n., Andrews, J. R., Bonilla, H. n., Hedlin, H. n., Jacobson, K. B., Balasubramanian, V. n., Purington, N. n., Kamble, S. n., de Vries, C. R., Quintero, O. n., Feng, K. n., Ley, C. n., Winslow, et al  
2021; 12 (1): 1967
- **Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.** *The Lancet. Respiratory medicine*  
Feld, J. J., Kandel, C. n., Biondi, M. J., Kozak, R. A., Zahoor, M. A., Lemieux, C. n., Borgia, S. M., Boggild, A. K., Powis, J. n., McCready, J. n., Tan, D. H., Chan, T. n., Coburn, et al  
2021

- **Progenitor identification and SARS-CoV-2 infection in human distal lung organoids.** *Nature*  
Salahudeen, A. A., Choi, S. S., Rustagi, A., Zhu, J., van Unen, V., de la O, S. M., Flynn, R. A., Margalef-Catala, M., Santos, A. J., Ju, J., Batish, A., Usui, T., Zheng, et al  
2020
- **High Prevalence of Chronic Viral Hepatitis and Liver Fibrosis Among Mongols in Southern California.** *Digestive diseases and sciences*  
Fong, T., Lee, B. T., Chang, M., Nasanbayar, K., Tsogtoo, E., Boldbaatar, D., Dashdorj, E. D., Clifford, N. E., Dashdorj, A. N., Bang, B., Chida, T., Lim, C., Sugiyama, et al  
2020
- **A Phase 2 Study of Peginterferon Lambda, Lonafarnib and Ritonavir for 24 Weeks: End-of-Treatment Results from the LIFT HDV Study**  
Koh, C., Hercun, J., Rahman, F., Huang, A., Da, B., Surana, P., Kapuria, D., Rotman, Y., Vittal, A., Gilman, C., Ben Yakov, G., Lai, W., Dahari, et al  
ELSEVIER.2020: S130
- **RNA genome conservation and secondary structure in SARS-CoV-2 and SARS-related viruses: a first look.** *RNA (New York, N.Y.)*  
Rangan, R., Zheludev, I. N., Das, R.  
2020
- **COVID-19 and emerging viral infections: The case for interferon lambda.** *The Journal of experimental medicine*  
Prokunina-Olsson, L., Alphonse, N., Dickenson, R. E., Durbin, J. E., Glenn, J. S., Hartmann, R., Kotenko, S. V., Lazear, H. M., O'Brien, T. R., Odendall, C., Onabajo, O. O., Piontkivska, H., Santer, et al  
2020; 217 (5)
- **Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity** *NATURE CANCER*  
Carozza, J. A., Bohnert, V., Nguyen, K. C., Skariah, G., Shaw, K. E., Brown, J. A., Rafat, M., von Eyben, R., Graves, E. E., Glenn, J. S., Smith, M., Li, L.  
2020; 1 (2): 184-+
- **Extracellular cGAMP is a cancer cell-produced immunotransmitter involved in radiation-induced anti-cancer immunity.** *Nature cancer*  
Carozza, J. A., Böhnert, V., Nguyen, K. C., Skariah, G., Shaw, K. E., Brown, J. A., Rafat, M., von Eyben, R., Graves, E. E., Glenn, J. S., Smith, M., Li, L.  
2020; 1 (2): 184-196
- **PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma.** *Science translational medicine*  
Tan, X. n., Banerjee, P. n., Pham, E. A., Rutaganira, F. U., Basu, K. n., Bota-Rabassedas, N. n., Guo, H. F., Grzeskowiak, C. L., Liu, X. n., Yu, J. n., Shi, L. n., Peng, D. H., Rodriguez, et al  
2020; 12 (527)
- **A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.** *Nature*  
Dinnon, K. H., Leist, S. R., Schäfer, A. n., Edwards, C. E., Martinez, D. R., Montgomery, S. A., West, A. n., Yount, B. L., Hou, Y. J., Adams, L. E., Gully, K. L., Brown, A. J., Huang, et al  
2020
- **Structure of the neurotensin receptor 1 in complex with β-arrestin 1.** *Nature*  
Huang, W. n., Masureel, M. n., Qianhui, Q. n., Janetzko, J. n., Inoue, A. n., Kato, H. E., Robertson, M. J., Nguyen, K. C., Glenn, J. S., Skiniotis, G. n., Kobilka, B. K.  
2020
- **Materials science approaches in the development of broad-spectrum antiviral therapies.** *Nature materials*  
Cho, N. J., Glenn, J. S.  
2020
- **Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition.** *mBio*  
Tal, M. C., Torrez Dulgeroff, L. B., Myers, L. n., Cham, L. B., Mayer-Barber, K. D., Bohrer, A. C., Castro, E. n., Yiu, Y. Y., Lopez Angel, C. n., Pham, E. n., Carmody, A. B., Messer, R. J., Gars, et al  
2020; 11 (3)
- **CHARACTERIZATION OF HDV, HBsAg AND ALT KINETICS UNDER PEGINTERFERON-LAMBDA MONOTHERAPY: THE PHASE 2 LIMIT STUDY**  
Etzion, O., Duehren, S., Hamid, S. S., Lurie, Y., Gane, E. J., Yardeni, D., Nevo-Shor, A., Channa, S., Parkash, O., Uprichard, S. L., Gish, R. G., Cotler, S. J., Glenn, et al

WILEY.2019: 1496A–1497A

- **A PHASE 2 STUDY OF LONAFARNIB, RITONAVIR AND PEGINTERFERON LAMBDA FOR 24 WEEKS: INTERIM END-OF-TREATMENT RESULTS FROM THE LIFT HDV STUDY.**  
Koh, C., Da, B. L., Surana, P., Huang, A., Kapuria, D., Rotman, Y., Vittal, A., Gilman, C., Ben-Yakov, G., Lai, C., Kleiner, D., Rahman, F., Hercun, et al  
WILEY.2019: 1483A
- **2'3'-cGAMP is an immunotransmitter produced by cancer cells and regulated by ENPP1**  
Carozza, J., Bohnert, V., Shaw, K., Khanh Nyugen, Skariah, G., Brown, J., Rafat, M., von Eyben, R., Graves, E., Glenn, J., Smith, M., Li, L.  
AMER CHEMICAL SOC.2019
- **HBV/HDV Coinfection: A Challenge for Therapeutics.** *Clinics in liver disease*  
Koh, C., Da, B. L., Glenn, J. S.  
2019; 23 (3): 557–72
- **Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia** *JOURNAL OF VIRAL HEPATITIS*  
Mahale, P., Aka, P., Chen, X., Pfeiffer, R. M., Liu, P., Groover, S., Mendy, M., Njie, R., Goedert, J. J., Kirk, G. D., Glenn, J. S., O'Brien, T. R.  
2019; 26 (6): 738–49
- **Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy** *JOURNAL OF HEPATOLOGY*  
Yurdaydin, C., Abbas, Z., Buti, M., Cornberg, M., Esteban, R., Etzion, O., Ganes, E. J., Gish, R. G., Glenn, J. S., Hamids, S., Heller, T., Koh, C., Lampertico, et al  
2019; 70 (5): 1008–15
- **Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.** *Journal of hepatology*  
Yurdaydin, C., Abbas, Z., Buti, M., Cornberg, M., Esteban, R., Etzion, O., Gane, E. J., Gish, R. G., Glenn, J. S., Hamid, S., Heller, T., Koh, C., Lampertico, et al  
2019; 70 (5): 1008–15
- **End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection**  
Etzion, O., Hamid, S., Lurie, Y., Gane, E., Bader, N., Yardeni, D., Nevo-Shor, A., Channa, S. M., Mawani, M., Parkash, O., Yang, K., Longo, D., Gish, et al  
ELSEVIER SCIENCE BV.2019: E32
- **The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection** *JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY*  
Townsend, E. C., Zhang, G. Y., Ali, R., Firke, M., Moon, M., Han, M., Fram, B., Glenn, J. S., Kleiner, D. E., Koh, C., Heller, T.  
2019; 34 (4): 764–75
- **Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection** *VIRUSES-BASEL*  
Tsuge, M., Uchida, T., Walsh, K., Ishida, Y., Tateno, C., Kumar, U., Glenn, J. S., Koh, C., Heller, T., Uprichard, S. L., Dahari, H., Chayama, K.  
2019; 11 (3)
- **Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection.** *Viruses*  
Tsuge, M., Uchida, T., Walsh, K., Ishida, Y., Tateno, C., Kumar, U., Glenn, J. S., Koh, C., Heller, T., Uprichard, S. L., Dahari, H., Chayama, K.  
2019; 11 (3)
- **Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States** *HEPATOLOGY*  
Kim, D., Li, A. A., Perumpail, B. J., Gadiparthi, C., Kim, W., Cholankeril, G., Glenn, J. S., Harrison, S. A., Younossi, Z. M., Ahmed, A.  
2019; 69 (3): 1064–74
- **A functional subset of CD8(+) T cells during chronic exhaustion is defined by SIRP alpha expression** *NATURE COMMUNICATIONS*  
Myers, L. M., Tal, M., Dulgeroff, L., Carmody, A. B., Messer, R. J., Gulati, G., Yiu, Y., Staron, M. M., Angel, C., Sinha, R., Markovic, M., Pham, E. A., Fram, et al  
2019; 10
- **A functional subset of CD8+ T cells during chronic exhaustion is defined by SIRPalpha expression.** *Nature communications*  
Myers, L. M., Tal, M. C., Torrez Dulgeroff, L. B., Carmody, A. B., Messer, R. J., Gulati, G., Yiu, Y. Y., Staron, M. M., Angel, C. L., Sinha, R., Markovic, M., Pham, E. A., Fram, et al

2019; 10 (1): 794

- **The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection.** *Journal of gastroenterology and hepatology*  
Townsend, E. C., Zhang, G. Y., Ali, R., Firke, M., Moon, M. S., Han, M. A., Fram, B., Glenn, J. S., Kleiner, D. E., Koh, C., Heller, T.  
2019
- **Hepatitis D virus infection, cirrhosis, and hepatocellular carcinoma in The Gambia.** *Journal of viral hepatitis*  
Mahale, P., Aka, P., Chen, X., Pfeiffer, R. M., Liu, P., Groover, S., Mendy, M., Njie, R., Goedert, J. J., Kirk, G. D., Glenn, J. S., O'Brien, T. R.  
2019
- **Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017.** *Gastroenterology*  
Kim, D. n., Adejumo, A. C., Yoo, E. R., Iqbal, U. n., Li, A. A., Pham, E. A., Cholankeril, G. n., Glenn, J. S., Ahmed, A. n.  
2019
- **Fuzhenghuayu Decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis.** *Scientific reports*  
Liu, H. L., Lv, J. n., Zhao, Z. M., Xiong, A. M., Tan, Y. n., Glenn, J. S., Tao, Y. Y., Weng, H. L., Liu, C. H.  
2019; 9 (1): 18719
- **Pathogenesis of and New Therapies for Hepatitis D** *GASTROENTEROLOGY*  
Koh, C., Heller, T., Glenn, J. S.  
2019; 156 (2): 461+
- **Human iPS derived progenitors bioengineered into liver organoids using an inverted colloidal crystal poly (ethylene glycol) scaffold** *BIOMATERIALS*  
Ng, S., Saeb-Parsy, K., Blackford, S. J. I., Segal, J. M., Serra, M., Horcas-Lopez, M., No, D., Mastoridis, S., Jassem, W., Frank, C. W., Cho, N., Nakauchi, H., Glenn, et al  
2018; 182: 299–311
- **Pathogenesis of and New Therapies for Hepatitis D.** *Gastroenterology*  
Koh, C., Heller, T., Glenn, J. S.  
2018
- **A new dual-targeting real-time RT-PCR assay for hepatitis D virus RNA detection** *DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE*  
Wang, Y., Glenn, J. S., Winters, M. A., Shen, L., Choong, I., Shi, Y., Bi, S., Ma, L., Zeng, H., Zhang, F.  
2018; 92 (2): 112–17
- **Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016** *GASTROENTEROLOGY*  
Kim, D., Li, A. A., Gadiparthi, C., Khan, M., Cholankeril, G., Glenn, J. S., Ahmed, A.  
2018; 155 (4): 1154+
- **A Challenging Case of Triple Hepatitis Virus Infection: An Accurate Diagnostic Test for Hepatitis D Virus Is Urgently Needed**  
Choudhry, S. A., Reyes, K., Ishtiaq, R., Aslam, A., Glenn, J. S., Lau, D. T. Y.  
NATURE PUBLISHING GROUP.2018: S1245
- **Impact of Drug Overdose Deaths on Solid Organ Transplantation in the United States** *JOURNAL OF GENERAL INTERNAL MEDICINE*  
Cholankeril, G., Li, A. A., Cholankeril, R., Toll, A. E., Glenn, J. S., Ahmed, A.  
2018; 33 (9): 1423–25
- **Human iPS derived progenitors bioengineered into liver organoids using an inverted colloidal crystal poly (ethylene glycol) scaffold.** *Biomaterials*  
Ng, S. S., Saeb-Parsy, K., Blackford, S. J., Segal, J. M., Serra, M. P., Horcas-Lopez, M., No, D. Y., Mastoridis, S., Jassem, W., Frank, C. W., Cho, N. J., Nakauchi, H., Glenn, et al  
2018; 182: 299–311
- **Changing Trends in Etiology- and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States.** *Hepatology (Baltimore, Md.)*  
Kim, D., Li, A. A., Perumpail, B. J., Gadiparthi, C., Kim, W., Cholankeril, G., Glenn, J. S., Harrison, S. A., Younossi, Z. M., Ahmed, A.  
2018

- **Changing Trends in Etiology-based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016.** *Gastroenterology*  
Kim, D., Li, A. A., Gadiparthi, C., Khan, M. A., Cholankeril, G., Glenn, J. S., Ahmed, A.  
2018
- **Hepatitis D Viremia Among Injection Drug Users in San Francisco** *JOURNAL OF INFECTIOUS DISEASES*  
Mahale, P., Aka, P., Chen, X., Liu, P., Fram, B. J., Wang, A. S., Simenel, S., Tseng, F., Chen, S., Edlin, B. R., Glenn, J. S., O'Brien, T. R.  
2018; 217 (12): 1902–6
- **Impact of Drug Overdose Deaths on Solid Organ Transplantation in the United States.** *Journal of general internal medicine*  
Cholankeril, G., Li, A. A., Cholankeril, R., Toll, A. E., Glenn, J. S., Ahmed, A.  
2018
- **Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study** *HEPATOLOGY*  
Yurdaydin, C., Keskin, O., Kalkan, C., Karakaya, F., Caliskan, A., Karatayli, E., Karatayli, S., Bozdayi, A., Koh, C., Heller, T., Idilman, R., Glenn, J. S.  
2018; 67 (4): 1224–36
- **A research agenda for curing chronic hepatitis B virus infection** *HEPATOLOGY*  
Alter, H., Block, T., Brown, N., Brownstein, A., Brosgart, C., Chang, K., Chen, P., Chisari, F. V., Cohen, C., El-Serag, H., Feld, J., Gish, R., Glenn, et al  
2018; 67 (3): 1127–31
- **Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop** *ANTIVIRAL RESEARCH*  
Block, T. M., Alter, H., Brown, N., Brownstein, A., Brosgart, C., Chang, K., Chen, P., Cohen, C., El-Serag, H., Feld, J., Gish, R., Glenn, J., Greten, et al  
2018; 150: 93–100
- **Letter to the Editor regarding article "Emerging concepts for the treatment of hepatitis delta" [Menashe Elazar and Jeffrey S Glenn, Curr Opin Virol 24 (2017) 55-59] Reply** *CURRENT OPINION IN VIROLOGY*  
Elazar, M., Glenn, J.  
2018; 28: 169
- **Emerging Therapeutic Targets for Hepatitis Delta Virus Infection.** *Gastroenterology & hepatology*  
Glenn, J. S.  
2018; 14 (1): 47–49
- **Structure of an engineered IFN-lambda/IFN-lambda R1/IL-10R beta complex provides insight into the functional dichotomy of type III versus type I IFNs**  
Mendoza, J., Schneider, W. M., Hoffman, H., Vercauteren, K., Jude, K. M., Xiong, A., Moraga, I., Horton, T. M., Glenn, J. S., de Jonga, Y. P., Garcia, K.  
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD.2017: 46
- **Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus** *ANNALS OF INTERNAL MEDICINE*  
Mahale, P., Glenn, J. S., O'Brien, T. R.  
2017; 167 (10): 759–60
- **Prevalence of hepatitis D viremia among injection drug users in San Francisco**  
Mahale, P., Aka, P. V., Chen, X., Liu, P., Wang, A. S., Tseng, F., Chen, S., Edlin, B. R., Glenn, J. S., O'Brien, T.  
WILEY.2017: 100A
- **Modeling hepatitis delta virus dynamics during ritonavir boosted lonafarnib treatment-the LOWR HDV-3 study**  
Dubey, P., Koh, C., Surana, P., Uprichard, S. L., Han, M., Fryzek, N., Kapuria, D., Etzion, O., Takyar, V. K., Rotman, Y., Yurdaydin, C., Glenn, J. S., Cotler, et al  
WILEY.2017: 21A
- **Quantitative Evaluation of Viral Protein Binding to Phosphoinositide Receptors and Pharmacological Inhibition** *ANALYTICAL CHEMISTRY*  
Kim, S., Jackman, J. A., Elazar, M., Cho, S., Glenn, J. S., Cho, N.  
2017; 89 (18): 9742–50
- **Long-term culture of human liver tissue with advanced hepatic functions.** *JCI insight*  
Ng, S. S., Xiong, A., Nguyen, K., Masek, M., No, D. Y., Elazar, M., Shteyer, E., Winters, M. A., Voedisch, A., Shaw, K., Rashid, S. T., Frank, C. W., Cho, et al

2017; 2 (11)

- **Hepatitis delta infection - Current and new treatment options** *BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY*  
Elazar, M., Koh, C., Glenn, J. S.  
2017; 31 (3): 321–27
- **Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients With Chronic Hepatitis Delta Virus Infection** *HEPATOLOGY COMMUNICATIONS*  
Canini, L., Koh, C., Cotler, S. J., Uprichard, S. L., Winters, M. A., Han, M., Kleiner, D. E., Idilman, R., Yurdaydin, C., Glenn, J. S., Heller, T., Dahari, H.  
2017; 1 (4): 288–92
- **Emerging concepts for the treatment of hepatitis delta.** *Current opinion in virology*  
Elazar, M., Glenn, J. S.  
2017; 24: 55-59
- **The IFN- $\gamma$ -IFN- $\gamma$ R1-IL-10R $\beta$  Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity.** *Immunity*  
Mendoza, J. L., Schneider, W. M., Hoffmann, H., Vercauteren, K., Jude, K. M., Xiong, A., Moraga, I., Horton, T. M., Glenn, J. S., de Jong, Y. P., Rice, C. M., Garcia, K. C.  
2017; 46 (3): 379-392
- **The IFN- $\lambda$ -IFN- $\lambda$ R1-IL-10R $\beta$  Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity** *IMMUNITY*  
Mendoza, J. L., Schneider, W. M., Hoffmann, H., Vercauteren, K., Jude, K. M., Xiong, A., Moraga, I., Horton, T. M., Glenn, J. S., de Jong, Y. P., Rice, C. M., Garcia, K. C.  
2017; 46 (3): 379-392
- **Extracellular Matrix Functionalization and Huh-7.5 Cell Coculture Promote the Hepatic Differentiation of Human Adipose-Derived Mesenchymal Stem Cells in a 3D ICC Hydrogel Scaffold.** *ACS biomaterials science & engineering*  
Wang, Y., Lee, J. H., Shirahama, H., Seo, J., Glenn, J. S., Cho, N. J.  
2016; 2 (12): 2255-2265
- **Extracellular Matrix Functionalization and Huh-7.5 Cell Coculture Promote the Hepatic Differentiation of Human Adipose-Derived Mesenchymal Stem Cells in a 3D ICC Hydrogel Scaffold** *ACS BIOMATERIALS SCIENCE & ENGINEERING*  
Wang, Y., Lee, J., Shirahama, H., Seo, J., Glenn, J. S., Cho, N.  
2016; 2 (12): 2255-2265
- **ECM proteins in a microporous scaffold influence hepatocyte morphology, function, and gene expression** *SCIENTIFIC REPORTS*  
Wang, Y., Kim, M. H., Shirahama, H., Lee, J. H., Ng, S. S., Glenn, J. S., Cho, N.  
2016; 6
- **A novel quantitative microarray antibody capture (Q-MAC) assay identifies an extremely high HDV prevalence amongst HBV infected Mongolians.** *Hepatology*  
Chen, X., Oidovsambuu, O., Liu, P., Grosely, R., Elazar, M., Winn, V. D., Fram, B., Boa, Z., Dai, H., Dashtseren, B., Yagaanbuyant, D., Genden, Z., Dashdorj, et al  
2016
- **Characterization of HDV and HBV kinetics during acute co-infection and interferon-alpha treatment in uPA/SCID chimeric mice with humanized livers**  
Uchida, T., Walsh, K., Hiraga, N., Imamura, M., Koh, C., Glenn, J., Uprichard, S. L., Heller, T., Dahari, H., Chayama, K.  
WILEY.2016: 9A–10A
- **A Phase 2 Study Of Titrating-Dose Lonafarnib Plus Ritonavir In Patients With Chronic Hepatitis D: Interim Results From The Lonafarnib With Ritonavir In HDV-4 (LOWR HDV-4) Study**  
Wedemeyer, H., Port, K., Deterding, K., Wranke, A., Kirschner, J., Martins, E. B., Glenn, J., Cornberg, M., Manns, M. P.  
WILEY.2016: 121A–122A
- **The Prenylation Inhibitor Lonafarnib Can Induce Post-Treatment Alt Flares With Viral Clearance In Patients With Chronic Delta Hepatitis**  
Yurdaydin, C., Idilman, R., Kalkan, C., Karakaya, F., Kartal, A., Keskin, O., Karatayli, E., Karatayli, S. C., Bozdayi, A., Koh, C., Heller, T., Glenn, J.  
WILEY.2016: 927A
- **Exploring Optimal Dosing Of Lonafarnib With Ritonavir For The Treatment Of Chronic Delta Hepatitis-Interim Results From The Lowr Hdv-2 Study**  
Yurdaydin, C., Idilman, R., Kalkan, C., Karakaya, F., Kartal, A., Keskin, O., Karatayli, E., Karatayli, S. C., Bozdayi, A., Koh, C., Heller, T., Glenn, J.

WILEY.2016: 910A–911A

- **Reconstitution and Functional Analysis of a Full-Length Hepatitis C Virus NS5B Polymerase on a Supported Lipid Bilayer.** *ACS central science*  
Cho, N., Pham, E. A., Hagey, R. J., Lévêque, V. J., Ma, H., Klumpp, K., Glenn, J. S.  
2016; 2 (7): 456-466
- **Multistep Compositional Remodeling of Supported Lipid Membranes by Interfacially Active Phosphatidylinositol Kinases** *ANALYTICAL CHEMISTRY*  
Tabaei, S. R., Guo, F., Rutaganira, F. U., Vafaei, S., Choong, I., Shokat, K. M., Glenn, J. S., Cho, N.  
2016; 88 (10): 5042-5045
- **Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification** *NATURE CHEMICAL BIOLOGY*  
Deans, R. M., Morgens, D. W., Okesli, A., Pillay, S., Horlbeck, M. A., Kampmann, M., Gilbert, L. A., Li, A., Mateo, R., Smith, M., Glenn, J. S., Carette, J. E., Khosla, et al  
2016; 12 (5): 361-?
- **Profiling system-wide immune signaling in chronic viral infection and its response to viral clearance**  
Angel, C., Furman, D., Pham, E., Fram, B., Thai Nguyen, Ahmed, A., Grant, P., Maecker, H. T., Glenn, J., Davis, M. M.  
AMER ASSOC IMMUNOLOGISTS.2016
- **Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase III beta** *JOURNAL OF MEDICINAL CHEMISTRY*  
Rutaganira, F. U., Fowler, M. L., McPhail, J. A., Gelman, M. A., Nguyen, K., Xiong, A., Doman, G. L., Tayshanjian, B., Glenn, J. S., Shokat, K. M., Burke, J. E.  
2016; 59 (5): 1830-1839
- **Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase IIIβ.** *Journal of medicinal chemistry*  
Rutaganira, F. U., Fowler, M. L., McPhail, J. A., Gelman, M. A., Nguyen, K., Xiong, A., Doman, G. L., Tavshanjian, B., Glenn, J. S., Shokat, K. M., Burke, J. E.  
2016; 59 (5): 1830-1839
- **Future Therapy for Hepatitis B Virus: Role of Immunomodulators.** *Current hepatology reports*  
Pham, E. A., Perumpail, R. B., Fram, B. J., Glenn, J. S., Ahmed, A., Gish, R. G.  
2016; 15 (4): 237-244
- **Decline in Hepatitis C Virus-related Liver Transplantation Waitlist Registrations among Patients without Hepatocellular Carcinoma: Early Effect of Direct-Acting Antivirals?**  
Perumpail, R. B., Wong, R. J., Jayasekera, C. R., Gonzalez, S. A., Glenn, J. S., Younossi, Z. M., Ahmed, A.  
WILEY-BLACKWELL.2015: 1397A
- **Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial** *LANCET INFECTIOUS DISEASES*  
Koh, C., Canini, L., Dahari, H., Zhao, X., Uprichard, S. L., Haynes-Williams, V., Winters, M. A., Subramanya, G., Cooper, S. L., Pinto, P., Wolff, E. F., Bishop, R., Han, et al  
2015; 15 (10): 1167-1174
- **Hepatitis D in Children** *JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION*  
Xue, M. M., Glenn, J. S., Leung, D. H.  
2015; 61 (3): 271-281
- **Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis** *TRANSPLANT INFECTIOUS DISEASE*  
Perumpail, R. B., Wong, R. J., Ha, L. D., Pham, E. A., Wang, U., Luong, H., Kumari, R., Daugherty, T. J., Higgins, J. P., Younossi, Z. M., Kim, W. R., Glenn, J. S., Ahmed, et al  
2015; 17 (2): 275-278
- **Phosphatidylinositol 4,5-Bisphosphate Is an HCV NS5A Ligand and Mediates Replication of the Viral Genome.** *Gastroenterology*  
Cho, N., Lee, C., Pang, P. S., Pham, E. A., Fram, B., Nguyen, K., Xiong, A., Sklan, E. H., Elazar, M., Koytak, E. S., Kersten, C., Kanazawa, K. K., Frank, et al  
2015; 148 (3): 616-625

- **The interaction between the Hepatitis C proteins NS4B and NS5A is involved in viral replication.** *Virology*  
David, N., Yaffe, Y., Hagoel, L., Elazar, M., Glenn, J. S., Hirschberg, K., Sklan, E. H.  
2015; 475: 139-149
- **HCV NS5A Inhibitors: The Devil Is in the Details** *GASTROENTEROLOGY*  
Elazar, M., Glenn, J. S.  
2014; 147 (2): 273–77
- **Fialuridine Induces Acute Liver Failure in Chimeric TK-NOG Mice: A Model for Detecting Hepatic Drug Toxicity Prior to Human Testing.** *PLoS medicine*  
Xu, D., Nishimura, T., Nishimura, S., Zhang, H., Zheng, M., Guo, Y., Masek, M., Michie, S. A., Glenn, J., Peltz, G.  
2014; 11 (4)
- **Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing.** *PLoS medicine*  
Xu, D., Nishimura, T., Nishimura, S., Zhang, H., Zheng, M., Guo, Y., Masek, M., Michie, S. A., Glenn, J., Peltz, G.  
2014; 11 (4)
- **Enabling Autologous Human Liver Regeneration With Differentiated Adipocyte Stem Cells** *CELL TRANSPLANTATION*  
Xu, D., Nishimura, T., Zheng, M., Wu, M., Su, H., Sato, N., Lee, G., Michie, S., Glenn, J., Peltz, G.  
2014; 23 (12): 1573-1584
- **Understanding hepatitis delta virus dynamics and antiviral efficacy of the prenylation inhibitor lonafarnib**  
Canini, L., Koh, C., Cotler, S., Yurdaydin, C., Cooper, S., Cory, D., Haynes-Williams, V., Winters, M. A., Choong, I. C., Hoofnagle, J. H., Glenn, J., Heller, T., Dahari, et al  
WILEY-BLACKWELL.2014: 317A
- **Prenylation inhibition with lonafarnib decreases hepatitis D levels in humans**  
Koh, C., Yurdaydin, C., Cooper, S., Cory, D., Dahari, H., Haynes-Williams, V., Winters, M. A., Bys, M., Choong, I. C., Idilman, R., Keskin, O., Canini, L., Pinto, et al  
WILEY-BLACKWELL.2014: 1092A–1093A
- **The stanford institute for chemical biology.** *ACS chemical biology*  
Chen, J. K., Du Bois, J., Glenn, J., Herschlag, D., Khosla, C.  
2013; 8 (9): 1860-1861
- **Coinfection with hepatitis B and D: Epidemiology, prevalence and disease in patients in Northern California** *JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY*  
Gish, R. G., Yi, D. H., Kane, S., Clark, M., Mangahas, M., Baqai, S., Winters, M. A., Proudfoot, J., Glenn, J. S.  
2013; 28 (9): 1521-1525
- **The Anti-Genomic (Negative) Strand of Hepatitis C Virus Is Not Targetable by shRNA**  
Lisowski, L., Elazar, M., Chu, K., Glenn, J. S., Kay, M. A.  
NATURE PUBLISHING GROUP.2013: S75
- **Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity** *BIOORGANIC & MEDICINAL CHEMISTRY*  
Lasheen, D. S., Ismail, M. A., Abou El Ella, D. A., Ismail, N. S., Eid, S., Vleck, S., Glenn, J. S., Watts, A. G., Abouzid, K. A.  
2013; 21 (10): 2742-2755
- **The anti-genomic (negative) strand of Hepatitis C Virus is not targetable by shRNA.** *Nucleic acids research*  
Lisowski, L., Elazar, M., Chu, K., Glenn, J. S., Kay, M. A.  
2013; 41 (6): 3688-3698
- **Using Chimeric Mice with Humanized Livers to Predict Human Drug Metabolism and a Drug-Drug Interaction** *JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS*  
Nishimura, T., Hu, Y., Wu, M., Pham, E., Suemizu, H., Elazar, M., Liu, M., Idilman, R., Yurdaydin, C., Angus, P., Stedman, C., Murphy, B., Glenn, et al  
2013; 344 (2): 388-396
- **An HCV IRES element regulates viral replication independent of translation** *63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)*

- Pham, E. A., Cho, N., Pang, P. S., Leveque, V. J., Ma, H., Klumpp, K., Glenn, J.  
WILEY-BLACKWELL.2012: 706A–706A
- **Structural Map of a MicroRNA-122: Hepatitis C Virus Complex** *JOURNAL OF VIROLOGY*  
Pang, P. S., Pham, E. A., Elazar, M., Patel, S. G., Eckart, M. R., Glenn, J. S.  
2012; 86 (2): 1250-1254
  - **Simplified RNA secondary structure mapping by automation of SHAPE data analysis** *NUCLEIC ACIDS RESEARCH*  
Pang, P. S., Elazar, M., Pham, E. A., Glenn, J. S.  
2011; 39 (22)
  - **Using 'Humanized' TK-NOG mice to predict human drug metabolism and drug-drug interactions** *17th North American Regional International-Society-for-the-Study-of-Xenobiotics (ISSX) Meeting*  
Hu, Y., Nishimura, T., Wu, M., Suemizu, H., Elazar, M., Glenn, J., Hasegawa, M., Nakamura, M., Nomura, T., Chen, Y., Zheng, M., Fitch, W. L., Peltz, et al  
INFORMA HEALTHCARE.2011: 164–165
  - **Structural Linkage between Ligand Discrimination and Receptor Activation by Type I Interferons** *CELL*  
Thomas, C., Moraga, I., Levin, D., Krutzik, P. O., Podoplelova, Y., Trejo, A., Lee, C., Yarden, G., Vleck, S. E., Glenn, J. S., Nolan, G. P., Piehler, J., Schreiber, et al  
2011; 146 (4): 621-632
  - **NOVEL ANTI-HCV THERAPY: SINGLE SHRNA TARGETING BOTH STRANDS OF HCV**  
Lisowski, L., Elazar, M., Chu, K., Glenn, J. S., Kay, M. A.  
WILEY-BLACKWELL.2011: 418–19
  - **The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein** *VIROLOGY*  
Lee, C., Ma, H., Hang, J. Q., Leveque, V., Sklan, E. H., Elazar, M., Klumpp, K., Glenn, J. S.  
2011; 414 (1): 10-18
  - **Role for ADP Ribosylation Factor 1 in the Regulation of Hepatitis C Virus Replication** *JOURNAL OF VIROLOGY*  
Matto, M., Sklan, E. H., David, N., Melamed-Book, N., Casanova, J. E., Glenn, J. S., Aroeti, B.  
2011; 85 (2): 946-956
  - **NS4B Targets and Inhibitors** *HEPATITIS C: ANTIVIRAL DRUG DISCOVERY AND DEVELOPMENT*  
Elazar, M., Glenn, J. S.  
edited by Tan, S. L., He, Y. P.  
2011: 257–69
  - **Mixing the right hepatitis C inhibitor cocktail** *TRENDS IN MOLECULAR MEDICINE*  
Gelman, M. A., Glenn, J. S.  
2011; 17 (1): 34-46
  - **Hydrophobic nanoparticles improve permeability of cell-encapsulating poly(ethylene glycol) hydrogels while maintaining patternability** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Lee, W., Cho, N., Xiong, A., Glenn, J. S., Frank, C. W.  
2010; 107 (48): 20709-20714
  - **Mixing the right hepatitis C inhibitor cocktail.** *Trends in molecular medicine*  
Gelman, M. A., Glenn, J. S.  
2010
  - **The Future of HCV Therapy: NS4B as an Antiviral Target** *VIRUSES-BASEL*  
Dvory-Sobol, H., Pang, P. S., Glenn, J. S.  
2010; 2 (11): 2481-2492
  - **STRUCTURAL INSIGHTS INTO THE MECHANISM OF MICRORNA-MODULATED HCV TRANSLATION** *61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases*  
Pang, P. S., Pham, E. A., Patel, S. G., Winters, M. A., Eckart, M. R., Glenn, J. S.  
WILEY-BLACKWELL.2010: 816A–817A

- **IDENTIFICATION AND TARGETING OF VIRAL-HOST PROTEIN-PROTEIN INTERACTIONS USING A NOVEL MICROFLUIDICS AFFINITY ASSAY**  
Einav, S., Gerber, D., Glenn, J. S.  
WILEY-BLACKWELL.2010: 743A
- **Prevalence, Correlates, and Viral Dynamics of Hepatitis Delta among Injection Drug Users** *JOURNAL OF INFECTIOUS DISEASES*  
Kucirka, L. M., Farzadegan, H., Feld, J. J., Mehta, S. H., Winters, M., Glenn, J. S., Kirk, G. D., Segev, D. L., Nelson, K. E., Marks, M., Heller, T., Golub, E. T.  
2010; 202 (6): 845-852
- **Transdifferentiation of adipose-derived stem cells into hepatocytes: a new approach** *LIVER INTERNATIONAL*  
Lue, J., Lin, G., Ning, H., Xiong, A., Lin, C., Glenn, J. S.  
2010; 30 (6): 913-922
- **The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole Is Highly Synergistic with HCV Protease Inhibitors** *Annual Meeting of the Infectious-Diseases-Society-of-America*  
Einav, S., Dvory-Sobol, H., Gehrig, E., Glenn, J. S.  
OXFORD UNIV PRESS INC.2010: 65-74
- **A small molecule inhibits HCV replication and alters NS4B's subcellular distribution** *ANTIVIRAL RESEARCH*  
Bryson, P. D., Cho, N., Einav, S., Lee, C., Tai, V., Bechtel, J., Sivaraja, M., Roberts, C., Schmitz, U., Glenn, J. S.  
2010; 87 (1): 1-8
- **The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors.** *journal of infectious diseases*  
Einav, S., Sobol, H. D., Gehrig, E., Glenn, J. S.  
2010; 202 (1): 65-74
- **Development of novel therapies for hepatitis C** *ANTIVIRAL RESEARCH*  
Lemon, S. M., McKeating, J. A., Pietschmann, T., Frick, D. N., Glenn, J. S., Tellinghuisen, T. L., Symons, J., Furman, P. A.  
2010; 86 (1): 79-92
- **Six RNA Viruses and Forty-One Hosts: Viral Small RNAs and Modulation of Small RNA Repertoires in Vertebrate and Invertebrate Systems** *PLOS PATHOGENS*  
Parameswaran, P., Sklan, E., Wilkins, C., Burgon, T., Samuel, M. A., Lu, R., Ansel, K. M., Heissmeyer, V., Einav, S., Jackson, W., Doukas, T., Paranjape, S., Polacek, et al  
2010; 6 (2)
- **Identification of a Class of HCV Inhibitors Directed Against the Nonstructural Protein NS4B** *SCIENCE TRANSLATIONAL MEDICINE*  
Cho, N., Dvory-Sobol, H., Lee, C., Cho, S., Bryson, P., Masek, M., Elazar, M., Frank, C. W., Glenn, J. S.  
2010; 2 (15)
- **THE EVOLUTION OF HEPATITIS C VIRUS INNATE IMMUNE EVASION** *Western Regional Meeting of the American-Federation-for-Medical-Research*  
Pang, P. S., Planet, P. J., Pham, E. A., Glenn, J. S.  
LIPPINCOTT WILLIAMS & WILKINS.2010: 180-80
- **Mechanism of an Amphipathic alpha-Helical Peptide's Antiviral Activity Involves Size-Dependent Virus Particle Lysis** *ACS CHEMICAL BIOLOGY*  
Cho, N., Dvory-Sobol, H., Xiong, A., Cho, S., Frank, C. W., Glenn, J. S.  
2009; 4 (12): 1061-1067
- **The reliable targeting of specific drug release profiles by integrating arrays of different albumin-encapsulated microsphere types** *BIOMATERIALS*  
Lee, W., Wiseman, M. E., Cho, N., Glenn, J. S., Frank, C. W.  
2009; 30 (34): 6648-6654
- **The Anti-Hepatitis C Agent Nitazoxanide Induces Phosphorylation of Eukaryotic Initiation Factor 2 alpha Via Protein Kinase Activated by Double-Stranded RNA Activation** *GASTROENTEROLOGY*  
Elazar, M., Liu, M., Mckenna, S. A., Liu, P., Gehrig, E. A., Puglisi, J. D., Rossignol, J., Glenn, J. S.  
2009; 137 (5): 1827-1835

- **DIFFERENTIATION OF HUMAN ADIPOSE TISSUE STEM CELLS INTO HEPATOCYTES: ROOM FOR IMPROVEMENT**  
Lue, J., Glenn, J. S.  
JOHN WILEY & SONS INC.2009: 902A
- **The Effect of Donor Race on the Survival of Black Americans Undergoing Liver Transplantation for Chronic Hepatitis C** *LIVER TRANSPLANTATION*  
Pang, P. S., Kamal, A., Glenn, J. S.  
2009; 15 (9): 1126-1132
- **The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy** *PLOS ONE*  
Pang, P. S., Planet, P. J., Glenn, J. S.  
2009; 4 (8)
- **Alpha-Helical Peptide-Induced Vesicle Rupture Revealing New Insight into the Vesicle Fusion Process As Monitored in Situ by Quartz Crystal Microbalance-Dissipation and Reflectometry** *ANALYTICAL CHEMISTRY*  
Cho, N., Wang, G., Edvardsson, M., Glenn, J. S., Hook, F., Frank, C. W.  
2009; 81 (12): 4752-4761
- **AAV Based RNAi Therapies To Treat and/or Prevent HCV in Animal Models**  
Lisowski, L., Elazar, M., Grompe, M., Glenn, J. S., Kay, M. A.  
NATURE PUBLISHING GROUP.2009: S14
- **Mechanisms of HCV survival in the host** *NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY*  
Sklan, E. H., Charuworn, P., Pang, P. S., Glenn, J. S.  
2009; 6 (4): 217-227
- **Viral infection of human progenitor and liver-derived cells encapsulated in three-dimensional PEG-based hydrogel** *BIOMEDICAL MATERIALS*  
Cho, N., Elazar, M., Xiong, A., Lee, W., Chiao, E., Baker, J., Frank, C. W., Glenn, J. S.  
2009; 4 (1)
- **Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide** *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*  
Korba, B. E., Elazar, M., Lui, P., Rossignol, J., Glenn, J. S.  
2008; 52 (11): 4069-4071
- **PHARMACOLOGICAL INHIBITORS OF A NEW HEPATITIS C TARGET-RNA BINDING BY NS4B-DISCOVERED BY MICROFLUIDIC AFFINITY ANALYSIS** *59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases*  
Einav, S., Gerber, D., Bryson, P. D., Sklan, E., Elazar, M., Maerkl, S., Dvory, H. S., Machlin, E., Gu, W., Quake, S., Glenn, J. S.  
WILEY-BLACKWELL.2008: 356A-356A
- **A SMALL MOLECULE INHIBITS HCV REPLICATION BY DISRUPTING NS4B LOCALIZATION**  
Bryson, P. D., Cho, N., Einav, S., Lee, C., Tai, V., Bechtel, J., Sivaraja, M., Roberts, C. D., Schmitz, U., Glenn, J. S.  
JOHN WILEY & SONS INC.2008: 1167A
- **HEPATITIS C VIRAL GENOTYPE AGE IS A PREDICTOR OF THE CLINICAL RESPONSE TO INTERFERON THERAPY**  
Pang, P. S., Planet, P. J., Glenn, J. S.  
JOHN WILEY & SONS INC.2008: 763A
- **POTENTIAL ROLE FOR NITAZOXANIDE IN COMBINATION WITH STAT-C AGENTS FOR THE INHIBITION OF HCV REPLICATION WITHOUT THE DEVELOPMENT OF RESISTANCE**  
Korba, B., Elazar, M., Liu, P., Glenn, J. S., Rossignol, J.  
JOHN WILEY & SONS INC.2008: 356A
- **BINDING DYNAMICS OF HEPATITIS C VIRUS' NONSTRUCTURAL PROTEINS TO CELL AND MODEL MEMBRANES** *59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases*  
Cho, N., Frank, C. W., Glenn, J. S.  
WILEY-BLACKWELL.2008: 758A-759A
- **NITAZOXANIDE (NTZ) IS AN INDUCER EIF2A AND PKR PHOSPHORYLATION** *59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases*  
Elazar, M., Liu, M., McKenna, S., Liu, P., Gehrig, E. A., Elfert, A., Puglisi, J., Rossignol, J., Glenn, J. S.

WILEY-BLACKWELL.2008: 1151A–1151A

- **Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis** *NATURE BIOTECHNOLOGY*  
Einav, S., Gerber, D., Bryson, P. D., Sklan, E. H., Elazar, M., Maerkl, S. J., Glenn, J. S., Quake, S. R.  
2008; 26 (9): 1019-1027
- **Isolation and transcriptional profiling of purified hepatic cells derived from human embryonic stem cells** *STEM CELLS*  
Chiao, E., Elazar, M., Xing, Y., Xiong, A., Kmet, M., Millan, M. T., Glenn, J. S., Wong, W. H., Baker, J.  
2008; 26 (8): 2032-2041
- **A drug-controllable tag for visualizing newly synthesized proteins in cells and whole animals** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Lin, M. Z., Glenn, J. S., Tsien, R. Y.  
2008; 105 (22): 7744-7749
- **Isolation of human fetal liver progenitors and their enhanced proliferation by three-dimensional coculture with endothelial cells** *TISSUE ENGINEERING PART A*  
Xiong, A., Austin, T. W., Lagasse, E., Uchida, N., Tamaki, S., Bordier, B. B., Weissman, I. L., Glenn, J. S., Millan, M. T.  
2008; 14 (6): 995-1006
- **The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without ha-ras co-transfection** *HEPATOLOGY*  
Einav, S., Sklan, E. H., Moon, H. M., Gehrig, E., Liu, P., Hao, Y., Lowe, A. W., Glenn, J. S.  
2008; 47 (3): 827-835
- **Studies of the potential for resistance to nitazoxanide or tizoxanide** *43rd Annual Meeting of the European-Association-for-the-Study-of-the-Liver*  
Korba, B. E., Glenn, J. S., Ayers, M. S., Rossignol, J. F.  
ELSEVIER SCIENCE BV.2008: S11–S11
- **TBC1D20 is a Rab1 GTPase-activating protein that mediates hepatitis C virus replication** *JOURNAL OF BIOLOGICAL CHEMISTRY*  
Sklan, E. H., Serrano, R. L., Einav, S., Pfeffer, S. R., Lambright, D. G., Glenn, J. S.  
2007; 282 (50): 36354-36361
- **Hepatitis d. Current treatment options in gastroenterology**  
Koytak, E. S., Yurdaydin, C., Glenn, J. S.  
2007; 10 (6): 456-463
- **Creation of lipid partitions by deposition of amphipathic viral peptides** *LANGMUIR*  
Cho, N., Cho, S., Hardesty, J. O., Glenn, J. S., Frank, C. W.  
2007; 23 (21): 10855-10863
- **A Rab-GAP TBC domain protein binds hepatitis C virus NS5A and mediates viral replication** *JOURNAL OF VIROLOGY*  
Sklan, E. H., Staschke, K., Oakes, T. M., Elazar, M., Winters, M., Aroeti, B., Danieli, T., Glenn, J. S.  
2007; 81 (20): 11096-11105
- **Interim data from a randomized controlled trial of nitazoxanide-peginterferon-ribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4**  
Rossignol, J., Elfert, A., El-Gohary, Y., Keeffe, E. B., Glenn, J.  
JOHN WILEY & SONS INC.2007: 316A–317A
- **Employing two different quartz crystal microbalance models to study changes in viscoelastic behavior upon transformation of lipid vesicles to a bilayer on a gold surface** *ANALYTICAL CHEMISTRY*  
Chot, N., Kanazawa, K. K., Glenn, J. S., Frank, C. W.  
2007; 79 (18): 7027-7035
- **Employing an amphipathic viral peptide to create a lipid bilayer on Au and TiO<sub>2</sub>** *JOURNAL OF THE AMERICAN CHEMICAL SOCIETY*  
Cho, N., Cho, S., Cheong, K. H., Glenn, J. S., Frank, C. W.  
2007; 129 (33): 10050-?
- **Binding dynamics of hepatitis C virus' NS5A amphipathic peptide to cell and model membranes** *JOURNAL OF VIROLOGY*  
Cho, N., Cheong, K. H., Lee, C., Frank, C. W., Glenn, J. S.

2007; 81 (12): 6682-6689

- **The power of silence: Application of small interfering RNAs to gastrointestinal diseases** *GASTROENTEROLOGY*  
Sklan, E. H., Glenn, J. S.  
2007; 132 (7): 2291-2295
- **A putative Rab GTPase-activating protein binds hepatitis C virus NS5A and mediates viral replication**  
Sklan, E. H., Staschke, K., Myers, T. M., Glenn, J. S.  
JOHN WILEY & SONS INC.2006: 692A
- **Molecular virology of the hepatitis C virus: Implication for novel therapies** *INFECTIOUS DISEASE CLINICS OF NORTH AMERICA*  
Glenn, J. S.  
2006; 20 (1): 81-?
- **Prenylation of HDAG and antiviral drug development** *HEPATITIS DELTA VIRUS*  
Glenn, J. S.  
2006; 307: 133-149
- **Novel therapies for hepatitis C virus based on lessons from virology.** *Clinical gastroenterology and hepatology*  
Glenn, J. S.  
2005; 3 (10): S86-8
- **Molecular virology of the hepatitis C virus: implication for novel therapies.** *Clinics in liver disease*  
Glenn, J. S.  
2005; 9 (3): 353-?
- **Confronting New and Old Antiviral Threats: Broad Spectrum Potential of Prenylation Inhibitors** *ANTIVIRAL DRUG DISCOVERY FOR EMERGING DISEASES AND BIOTERRORISM THREATS*  
Elazar, M., Glenn, J. S.  
edited by Torrence, P. F.  
2005: 249-61
- **Hepatitis C virus core protein associates with detergent-resistant membranes distinct from classical plasma membrane rafts** *JOURNAL OF VIROLOGY*  
Matto, M., Rice, C. M., Aroeti, B., Glenn, J. S.  
2004; 78 (21): 12047-12053
- **An n-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication** *JOURNAL OF VIROLOGY*  
Elazar, M., Liu, P., Rice, C. M., Glenn, J. S.  
2004; 78 (20): 11393-11400
- **A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication** *JOURNAL OF VIROLOGY*  
Einav, S., Elazar, M., Danieli, T., Glenn, J. S.  
2004; 78 (20): 11288-11295
- **Overdependence on the host-an Achilles' heel of HCV?** *Hepatology*  
Glenn, J. S.  
2004; 39 (6): 1734-1735
- **Testing antivirals against hepatitis delta virus: farnesyl transferase inhibitors.** *Methods in molecular medicine*  
Bordier, B. B., Glenn, J. S.  
2004; 96: 539-553
- **Prenylation inhibitors: a novel class of antiviral agents** *JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY*  
Einav, S., Glenn, J. S.  
2003; 52 (6): 883-886
- **In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus** *JOURNAL OF CLINICAL INVESTIGATION*  
Bordier, B. B., Ohkanda, J., Liu, P., Lee, S. Y., Salazar, F. H., Marion, P. L., Ohashi, K., Meuse, L., Kay, M. A., Casey, J. L., Sebt, S. M., Hamilton, A. D., Glenn, et al

---

2003; 112 (3): 407-414

- **Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication** *JOURNAL OF VIROLOGY*  
Elazar, M., Cheong, K. H., Liu, P., Greenberg, H. B., Rice, C. M., Glenn, J. S.  
2003; 77 (10): 6055-6061
- **A prenylation inhibitor prevents production of infectious hepatitis delta virus particles** *JOURNAL OF VIROLOGY*  
Bordier, B. B., Marion, P. L., Ohashi, K., Kay, M. A., Greenberg, H. B., Casey, J. L., Glenn, J. S.  
2002; 76 (20): 10465-10472
- **Membrane association of HCVNS5A: A novel antiviral target.**  
Elazar, M., Liu, P., Greenberg, H. B., Rice, C. M., Glenn, J. S.  
W B SAUNDERS CO.2001: 440A
- **Host-microbe interactions: viruses - Lessons in defense: hepatitis C, a case study - Editorial overview** *CURRENT OPINION IN MICROBIOLOGY*  
Cooper, S. S., Glenn, J., Greenberg, H. B.  
2000; 3 (4): 363-365
- **Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses** *NATURE MEDICINE*  
Ohashi, K., Marion, P. L., Nakai, H., Meuse, L., Cullen, J. M., Bordier, B. B., Schwall, R., Greenberg, H. B., Glenn, J. S., Kay, M. A.  
2000; 6 (3): 327-331
- **Shutting the door on hepatitis delta virus (HDV): Sensitivity to prenylation inhibition prompts new therapeutic strategy** *Viral Hepatitis Reviews*  
Glenn JS  
1999; 53: 13-26
- **Use of a prenylation inhibitor as a novel antiviral agent** *JOURNAL OF VIROLOGY*  
Glenn, J. S., Marsters, J. C., Greenberg, H. B.  
1998; 72 (11): 9303-9306
- **Finding the iron in the melting pot - Practical use of a new genetic assay for hereditary hemochromatosis** *WESTERN JOURNAL OF MEDICINE*  
Glenn, J. S., Cheung, R. C.  
1998; 168 (6): 525-527
- **DELIVERY OF LIPOSOME-ENCAPSULATED RNA TO CELLS EXPRESSING INFLUENZA-VIRUS HEMAGGLUTININ** *METHODS IN ENZYMOLOGY*  
Glenn, J. S., Ellens, H., White, J. M.  
1993; 221: 327-339
- **IDENTIFICATION OF A PRENYLATION SITE IN DELTA-VIRUS LARGE ANTIGEN** *SCIENCE*  
Glenn, J. S., Watson, J. A., HAVEL, C. M., White, J. M.  
1992; 256 (5061): 1331-1333
- **TRANSDOMINANT INHIBITION OF HUMAN HEPATITIS-DELTA VIRUS GENOME REPLICATION** *JOURNAL OF VIROLOGY*  
Glenn, J. S., White, J. M.  
1991; 65 (5): 2357-2361
- **REPLICATION OF MONOMERIC GENOMIC-DELTA RNA IN CULTURED-CELLS** *3RD INTERNATIONAL SYMP ON HEPATITIS DELTA VIRUS*  
Glenn, J. S., Taylor, J., White, J. M.  
WILEY-LISS, INC.1991: 293-297
- **DELIVERY OF MACROMOLECULES INTO CELLS EXPRESSING A VIRAL MEMBRANE-FUSION PROTEIN** *METHODS IN CELL BIOLOGY*  
Ellens, H., Doxsey, S., Glenn, J. S., White, J. M.  
1989; 31: 155-176

## PRESENTATIONS

- Novel Diagnosis and Treatment with Prenylation Inhibitors for Hepatitis Delta. - APASL Annual Meeting (2/2017)
- HDV-Specific Targets - AASLD/EASL HBV Treatment Endpoints Workshop (9/2016)
- Management of Hepatitis B and D--Novel Therapeutic Options: Prenylation Inhibitors for Treating Delta Hepatitis. - The 8th Annual Meeting of Asia-Pacific Alliance of Liver Diseases (9/2016)
- Prenylation Inhibitors for Treating Delta Hepatitis. - Onum Foundation (6/2016)
- Translating Molecular Virology into Novel Antiviral Strategies - Israel Association for the Study of Liver Disease Annual Meeting (6/2016)
- Prenylation Inhibitors for Treating Delta Hepatitis. - Israel Association for the Study of Liver Disease Annual Meeting (6/2016)
- Translating Molecular Virology into Novel Antiviral Strategies - Nanyang Technological University (4/2016)
- Targeting Prenylation to Inhibit Hepatitis Delta Virus Infections. - The International Symposium on Chemical Biology (1/2016)
- Translating Molecular Virology into Novel Antiviral Strategies - UC San Francisco (1/2016)
- Hepatitis Delta Virus (HDV): The Next Frontier in Viral Hepatitis - CME, AASLD (11/2015)
- The Role of Prenylation Inhibitors for the Treatment of Hepatitis D (delta). - The Global Viral Hepatitis Summit, 15th International Symposium on Viral Hepatitis and Liver Disease (6/2015)
- Hepatitis D Virus Life Cycle and Basis for Prenylation Inhibition Based Antiviral Therapy - Mongolian Digestive Disease Week Hepatology Day (5/2015)
- Targeting Prenylation to Inhibit Hepatitis Delta Virus Infections. - 5th Bay Area Symposium on Viruses (5/2015)
- Dose-Dependent Decrease in Hepatitis Delta Virus (HDV) RNA Achieved with the Oral Prenylation Inhibitor Ionafarnib in a Proof-Of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study... - Viral Hepatitis 2015 (4/2015)
- Prenylation-Inhibition Based Anti-HDV Therapy - Viral Hepatitis Grand Rounds (12/2014)
- Rationale for Prenylation-Inhibition Based Anti-HDV Therapy - Hepatitis Delta International Network AASLD (11/2014)
- Translating Molecular Virology into Novel Therapies for Hepatitis and New Approaches to Drug Development - Ankara University (5/2014)
- Taking Down Hepatitis C - American Society for Clinical Pharmacology and Therapeutics Annual Meeting (3/2014)
- Translating Molecular Virology into Novel Antiviral Therapies - "From Genes to Drugs: Translating Basic Mechanisms in Digestive Diseases" Symposium, Digestive Disease Week (5/2013)
- Translating Molecular Virology into Novel Therapies for Hepatitis - Inauguration Symposium of Ajou Translational Research Institute (5/2013)
- Interferon and New Treatments - AASLD Hepatitis B SIG Program on Delta Hepatitis (11/2012)
- Artificial Liver Platform for Next-Generation Drug Discovery and Development--Leveraging Engineered Human Liver Issues and Humanized Mice - Nanyang Technological University (10/2012)
- NS4B and PI-4III Kinase Inhibitors - S2E-HCV Workshop, Emory University (9/2012)
- Translating Molecular Virology into Novel Therapies for Hepatitis - Englert Lecture, Medical Grand Rounds (6/2012)
- Inhibitors of Other Viral Functions - AASLD Hepatitis Single Topic Conference, HCVDirect Antiviral Agents (DAA) (3/2012)
- Through Mice to Man: A New Potential Therapy for Hepatitis D; A New Model for Hepatitis C Virus and Early Drug Development; Human Liver Tissue Engineering and Pathway to in Vivo Assessment in Mice - 7th Annual SALAS Conference (12/2011)
- Translating Molecular Virology into Novel Therapies for Hepatitis - Nanyang Technological University (12/2011)
- Translating Molecular Virology into Novel Therapies for Hepatitis - The 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy (6/2011)
- Translating Molecular Virology into Novel Antiviral Therapies - 45th Joint Working Conference on Immunology and Viral Diseases, US-Japan Cooperative Medical Science Program (6/2011)
- Translating Molecular Virology into Novel Antiviral Strategies - GI Grand Rounds (5/2011)
- Translating Molecular Virology into Novel Antiviral Therapies for Hepatitis - The 12th International HIV Pharmacokinetic Workshop (4/2011)
- Hepatitis D Virus: the Virus, Disease and Therapy - The AASLD Postgraduate course, 2010 AASLD Annual Meeting (10/2010)
- Life Cycle and Potential Therapeutic Targets - The EASL Monothematic Conference on Delta Hepatitis (9/2010)
- New Approaches to Hepatitis C - The 2nd Molecular Viral Hepatitis Conference (6/2010)

- Next Generation Strategies for Hepatitis C - Department of Medicine Grand Rounds (12/2009)
- New Approaches to Hepatitis C - The 2009 UGA Conference on Drug Discovery (11/2009)
- Viral Pathogenesis and Underpinnings of HCV Treatment - The Infectious Diseases Society of America 47th Annual Meeting (10/2009)
- New Targets within NS4B - 22nd International Conference on Antiviral Research (5/2009)
- Small Molecule Approaches to NS4B and Other Novel Non-Structural Protein Target - Cambridge Health Tech Institute HCV Drug Discovery Conference (4/2009)
- High Throughput Screening for Anti-HCV Activity - The 13th International Symposium on Viral Hepatitis and Liver Disease (3/2009)
- Co-infections with HBV/HDV - Hepatitis B Foundation's 14th Annual Princeton Workshop (11/2008)
- Translating Hepatitis C Virus (HCV) Molecular Virology into Novel Antiviral Strategies (7/2007)
- Molecular Virology of The Hepatitis C Virus: Implication for Novel Therapies - 5th Annual Clinical Care Options for Hepatitis Symposium (7/2007)
- HCV Life Cycle and Novel Antiviral Targets - The Virology and Treatment of Hepatitis C Symposium (6/2007)
- Novel Targets in Hepatitis C Virus - Michigan Gastrointestinal Peptide Research Center (11/2006)
- Translating Molecular Virology into Novel Antiviral Strategies - Department of Medicine Grand Rounds (10/2006)
- Novel Antiviral Targets in Hepatitis C Virus - Division of Gastroenterology and Liver Center (3/2006)
- Novel Antiviral Targets in Hepatitis C Virus - Division of Gastroenterology and the NIH Center for Molecular Studies in Digestive and Liver Diseases (12/2005)
- Pharmacologic Targets in the HDV Life Cycle - European Association for the Study of the Liver Monothematic Conference (10/2005)
- Novel Antiviral Targets in Hepatitis C Virus. - Division of Gastroenterology, University of California (6/2005)
- Novel Therapies for HCV Based on Lessons from Virology - 2nd Joint Meeting of the Japanese Society of Gastroenterology and the American Gastroenterological Association (4/2005)
- HCV Viral Life Cycle and Targets for Drug Development - 55th Annual Meeting of the American Association for the Study of Liver Diseases Postgraduate Course (10/2004)
- Replication of Hepatitis D and Novel Targets for Antiviral Therapy - American Association for the Study of Liver Diseases Single Topic Conference (3/2004)
- New Antiviral Targets in Hepatitis C Virus - Center for the Study of Hepatitis C (10/2003)
- Inhibition of Prenylation: A Platform to Block Replication. - American Society for Microbiology Meeting (3/2003)
- Translating Molecular Virology into Novel Antiviral Therapies. - UCSF Liver Center (2/2003)
- Membrane association of HCV NS5A: Mechanism, Essential Role in RNA Replication, and Novel Antiviral Target - 1st Japan GRG/AGA Symposium (12/2002)
- Membrane Association of HCV NS5A: A Novel Antiviral Target - 52nd Annual Meeting of the American Association for the Study of Liver Diseases (11/2001)
- Mechanism of NS5A Membrane Association and Role in RNA Replication - 8th International Symposium on Hepatitis C Virus & Related Viruses (9/2001)
- Prospects of Prenylation Inhibition-Based Anti-HDV Therapy - The International Symposium on Viral Hepatitis and Liver Disease (4/2000)
- A prenylation inhibitor prevents HDV assembly - The Molecular Biology of Hepatitis B Viruses 1999 Meeting (8/1999)
- Hepatitis Delta Virus: Molecular Biology, Assembly, and Implications for Antiviral Therapies - Liver Center, Hadassah Medical School (5/1999)
- Prenylation Inhibition: Prospects for A Novel Approach to Anti-Hepatitis Delta Virus Therapy - Division of Gastroenterology Grand Round (9/1998)
- Prenylation inhibitors as a novel antiviral therapy - 8th Annual Stanford/UCSF Research Conference Program (11/1997)
- An Assay for Novel Antiviral Agents - American Association for the Study of Liver Diseases Single Topic Conference (6/1997)
- Hepatitis Delta Virus--Replication, Prenylation, and Antiviral Therapies - Chiron Corporation (10/1993)
- Novel Targets of Anti-Hepatitis Delta Virus Therapy - The Fourth International Symposium on Hepatitis Delta Virus and Liver Disease (6/1992)
- Replication of The Hepatitis Delta Virus--Thesis Defense - Department of Biochemistry and Biophysics, U.C. San Francisco (3/1992)
- The Molecular Biology of Hepatitis Delta Virus - Department of Surgery Grand Rounds (2/1992)

- Role of the Carboxy Terminus of Delta Antigen in Hepatitis Delta Virus (HDV) Replication - International Meeting on the Molecular Biology of the Hepatitis B Viruses (10/1991)
- Inhibition of Hepatitis Delta Virus Genome Replication - American Federation for Clinical Research, National Meeting (5/1991)
- Trans-Dominant Inhibition of Hepatitis Delta Virus Replication - Department of Laboratory Medicine Seminar (3/1991)
- Hemagglutinin-,Mediated Liposome Delivery; Application to The Study of Hepatitis Delta Virus. - Invited Seminar Speaker Series (11/1990)
- Initiation of Faithful Delta Virus Genome Replication - Department of Laboratory Medicine Seminar (2/1990)
- Replication of Delta RNA in Cultured Cells. - The Third International Symposium on Hepatitis Delta Virus (10/1989)